Edition:
India

Poxel Initiates Phase 1B MAD Trial For Nash Drug Candidate


Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - Poxel SA ::POXEL INITIATES PHASE 1B MULTIPLE ASCENDING DOSE (MAD) TRIAL FOR NASH DRUG CANDIDATE, PXL065.PHASE 1B MAD TRIAL IS DESIGNED TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) AND SUPPORT DOSE SELECTION FOR A PIVOTAL STUDY; TOPLINE RESULTS EXPECTED IN Q4 2019.RESULTS FROM PHASE 1A SINGLE ASCENDING DOSE (SAD) STUDY OF PXL065 TO BE PRESENTED AT AMERICAN ASSOCIATION FOR STUDY OF LIVER DISEASES (AASLD) ANNUAL MEETING, NOVEMBER 8-12, 2019 IN BOSTON, MA.POXEL WILL MEET WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN EARLY Q4 2019 TO DISCUSS REGISTRATION PROGRAM AND 505(B)(2) REGULATORY PATHWAY. 

Company Quote

8.4
0.12 +1.45%
21 Oct 2019